Di Caro V, Pandey K, Lizama B, et al. Proteomic Analysis in a Phase 2 Clinical Trial Studying CT1812 to Identify CSF and Plasma Pharmacodynamic Biomarkers and Molecular Correlates of EEG in Alzheimer’s Patients. Poster presented Oct 2023 at: Clinical Trials on Alzheimer’s Disease (CTAD); Boston, Massachusetts.
Lizama B, Cho E, Duong D, et al. Proteomic Analysis of Plasma in a Phase 2 Clinical Trial in Alzheimer’s Patients to Identify Pharmacodynamic Biomarkers of the S2R Modulator CT1812. Poster presented Oct 2023 at: Clinical Trials on Alzheimer’s Disease (CTAD); Boston, Massachusetts.
Di Caro V, Cho E, Caldwell J, et al. Brain transcriptomic and proteomic analyses in an in vivo AD model further elucidate the role of the sigma-2 receptor modulator CT1812 in Alzheimer’s disease. Poster presented at: 2023 Alzheimer’s Association’s International Conference (AAIC); Amsterdam, The Netherlands.
Pandey K, Duong D, Waybright L, et al. Pharmacodynamic Effects of the S2R Modulator CT1812 in Alzheimer’s Disease (AD) Patients Observed in a Meta-analysis of CSF Proteomes from SPARC and SHINE Part A. Poster presented at: AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases
Lizama B, Waybright L, Malagise E, et al. Unbiased Transcriptomic Analysis of the sigma-2 Modulator, CT1812 in Cell-based Models of Dry Age-related Macular Degeneration. Poster presented at: 2023 Association for Research in Vision & Ophthalmology
Galvin JE, Tolea MI, Hamby ME, et al. A Randomized, Double-blind, Placebo-controlled, Phase 2, Six-month Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of CT1812 in Participants with Mild-to-Moderate Dementia with Lewy Bodies. Poster presented at: 2022 Clinical Trials on Alzheimer’s Disease Congress (CTAD); San Francisco, CA.
Seyfried N, Waybright L, Duong D, et al. Proteomic Analysis of CSF in a Phase 2 Clinical Trial for AD to Identify Pharmacodynamic Biomarkers of the S2R Modulator CT1812. Poster presented at: AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases; Barcelona, Spain.
Malagise E, Keeling E, Knezovich N, et al. Sigma-2 receptor modulators rescue POS trafficking deficits in RPE cell-based models of dry AMD. Poster presented at: 2022 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO); Denver, CO.
Izzo NJ, LaBarbera KM, Yuede CM, et al. Experimental Therapeutic CT1812 Demonstrates Target Engagement in a Phase 1b Clinical Trial to Measure Displacement of Aβ Oligomers Into CSF. Poster presented at: AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases; Barcelona, Spain.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
